Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors

Koji Harada, Tarannum Ferdous, Dan Cui, Yasuhiro Kuramitsu, Takuya Matsumoto, Eiji Ikeda, Hideyuki Okano, Yoshiya Ueyama

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The cancer stem cells (CSCs), a small subpopulation of cells in tumor are responsible for the tumor initiation, growth, recurrence and metastasis of cancer, as well as resistance of cancers to drugs or radiotherapy. CSCs are an important target for the development of novel strategies in cancer treatment. However, CSCs-targeted new anti-cancer drug discovery is currently hindered by the lack of easy and reliable methods for isolating, collecting and maintaining sufficient number of CSCs. Here, we examined whether introduction of defined reprogramming factors (Oct4, shp53, Sox2, Klf4, l-Myc and Lin28) into HSC2 tongue cancer cells could transform the HSC2 into HSC2 with CSCs properties. Methods: We introduced the defined reprogramming factors into HSC2 tongue cancer cells via episomal vectors by electroporation method to generate transfectant cells. We investigated the malignant properties of the transfectant cells by cell proliferation assay, migration assay, wound healing assay, sphere formation assay, chemosensitivity and radiosensitivity assay in vitro; and also examined the tumorigenic potential of the transfectants in vivo. Results: The transfectant cells (HSC2/hOCT3/4-shp53-F, HSC2/hSK, HSC2/hUL, HSC2/hOCT3/4-shp53-F + hSK, HSC2/hOCT3/4-shp53-F + hUL, HSC2/hSK + hUL, HSC2/hOCT3/4-shp53-F + hSK + hUL) displayed a malignant phenotype in culture and form tumors on the back of nude mice more efficiently than parental HSC2 and control HSC2/EGFP transfectant cells. They exhibited increased resistance to chemotherapeutic agents; 5-fluorouracil, cisplatin, docetaxel, trifluorothymidine, zoledronic acid, cetuximab, bortezomib and radiation when compared with HSC2 and HSC2/EGFP. Among all the transfected cells, HSC2/hOCT3/4-shp53-F + hSK + hUL cell containing all of the reprogramming factors showed the most aggressive and malignant properties and presented the highest number of spheres in the culture medium containing human recombinant fibroblast Growth Factor-2 (FGF-2) and epidermal Growth Factor (EGF). Conclusion: These findings suggest that artificial cancer stem cells obtained by the induction of cellular reprogramming may be useful for investigating the acquisition of potential malignancy as well as screening the CSCs-targeting drugs.

Original languageEnglish
Article number548
JournalBMC Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - 2016 Jul 27

Fingerprint

Tongue Neoplasms
Neoplastic Stem Cells
Neoplasms
zoledronic acid
docetaxel
Trifluridine
Cellular Reprogramming
Electroporation
Radiation Tolerance
Fibroblast Growth Factor 2
Drug Discovery
Drug Delivery Systems
Epidermal Growth Factor
Nude Mice
Fluorouracil
Wound Healing
Cisplatin
Culture Media
Radiotherapy
Cell Proliferation

Keywords

  • Artificial CSC
  • Episomal vector
  • Reprogramming factor
  • Tongue cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Harada, K., Ferdous, T., Cui, D., Kuramitsu, Y., Matsumoto, T., Ikeda, E., ... Ueyama, Y. (2016). Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors. BMC Cancer, 16(1), [548]. https://doi.org/10.1186/s12885-016-2416-9

Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors. / Harada, Koji; Ferdous, Tarannum; Cui, Dan; Kuramitsu, Yasuhiro; Matsumoto, Takuya; Ikeda, Eiji; Okano, Hideyuki; Ueyama, Yoshiya.

In: BMC Cancer, Vol. 16, No. 1, 548, 27.07.2016.

Research output: Contribution to journalArticle

Harada, K, Ferdous, T, Cui, D, Kuramitsu, Y, Matsumoto, T, Ikeda, E, Okano, H & Ueyama, Y 2016, 'Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors', BMC Cancer, vol. 16, no. 1, 548. https://doi.org/10.1186/s12885-016-2416-9
Harada, Koji ; Ferdous, Tarannum ; Cui, Dan ; Kuramitsu, Yasuhiro ; Matsumoto, Takuya ; Ikeda, Eiji ; Okano, Hideyuki ; Ueyama, Yoshiya. / Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors. In: BMC Cancer. 2016 ; Vol. 16, No. 1.
@article{d54d12a051e548bf88daa02efc91cc92,
title = "Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors",
abstract = "Background: The cancer stem cells (CSCs), a small subpopulation of cells in tumor are responsible for the tumor initiation, growth, recurrence and metastasis of cancer, as well as resistance of cancers to drugs or radiotherapy. CSCs are an important target for the development of novel strategies in cancer treatment. However, CSCs-targeted new anti-cancer drug discovery is currently hindered by the lack of easy and reliable methods for isolating, collecting and maintaining sufficient number of CSCs. Here, we examined whether introduction of defined reprogramming factors (Oct4, shp53, Sox2, Klf4, l-Myc and Lin28) into HSC2 tongue cancer cells could transform the HSC2 into HSC2 with CSCs properties. Methods: We introduced the defined reprogramming factors into HSC2 tongue cancer cells via episomal vectors by electroporation method to generate transfectant cells. We investigated the malignant properties of the transfectant cells by cell proliferation assay, migration assay, wound healing assay, sphere formation assay, chemosensitivity and radiosensitivity assay in vitro; and also examined the tumorigenic potential of the transfectants in vivo. Results: The transfectant cells (HSC2/hOCT3/4-shp53-F, HSC2/hSK, HSC2/hUL, HSC2/hOCT3/4-shp53-F + hSK, HSC2/hOCT3/4-shp53-F + hUL, HSC2/hSK + hUL, HSC2/hOCT3/4-shp53-F + hSK + hUL) displayed a malignant phenotype in culture and form tumors on the back of nude mice more efficiently than parental HSC2 and control HSC2/EGFP transfectant cells. They exhibited increased resistance to chemotherapeutic agents; 5-fluorouracil, cisplatin, docetaxel, trifluorothymidine, zoledronic acid, cetuximab, bortezomib and radiation when compared with HSC2 and HSC2/EGFP. Among all the transfected cells, HSC2/hOCT3/4-shp53-F + hSK + hUL cell containing all of the reprogramming factors showed the most aggressive and malignant properties and presented the highest number of spheres in the culture medium containing human recombinant fibroblast Growth Factor-2 (FGF-2) and epidermal Growth Factor (EGF). Conclusion: These findings suggest that artificial cancer stem cells obtained by the induction of cellular reprogramming may be useful for investigating the acquisition of potential malignancy as well as screening the CSCs-targeting drugs.",
keywords = "Artificial CSC, Episomal vector, Reprogramming factor, Tongue cancer",
author = "Koji Harada and Tarannum Ferdous and Dan Cui and Yasuhiro Kuramitsu and Takuya Matsumoto and Eiji Ikeda and Hideyuki Okano and Yoshiya Ueyama",
year = "2016",
month = "7",
day = "27",
doi = "10.1186/s12885-016-2416-9",
language = "English",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors

AU - Harada, Koji

AU - Ferdous, Tarannum

AU - Cui, Dan

AU - Kuramitsu, Yasuhiro

AU - Matsumoto, Takuya

AU - Ikeda, Eiji

AU - Okano, Hideyuki

AU - Ueyama, Yoshiya

PY - 2016/7/27

Y1 - 2016/7/27

N2 - Background: The cancer stem cells (CSCs), a small subpopulation of cells in tumor are responsible for the tumor initiation, growth, recurrence and metastasis of cancer, as well as resistance of cancers to drugs or radiotherapy. CSCs are an important target for the development of novel strategies in cancer treatment. However, CSCs-targeted new anti-cancer drug discovery is currently hindered by the lack of easy and reliable methods for isolating, collecting and maintaining sufficient number of CSCs. Here, we examined whether introduction of defined reprogramming factors (Oct4, shp53, Sox2, Klf4, l-Myc and Lin28) into HSC2 tongue cancer cells could transform the HSC2 into HSC2 with CSCs properties. Methods: We introduced the defined reprogramming factors into HSC2 tongue cancer cells via episomal vectors by electroporation method to generate transfectant cells. We investigated the malignant properties of the transfectant cells by cell proliferation assay, migration assay, wound healing assay, sphere formation assay, chemosensitivity and radiosensitivity assay in vitro; and also examined the tumorigenic potential of the transfectants in vivo. Results: The transfectant cells (HSC2/hOCT3/4-shp53-F, HSC2/hSK, HSC2/hUL, HSC2/hOCT3/4-shp53-F + hSK, HSC2/hOCT3/4-shp53-F + hUL, HSC2/hSK + hUL, HSC2/hOCT3/4-shp53-F + hSK + hUL) displayed a malignant phenotype in culture and form tumors on the back of nude mice more efficiently than parental HSC2 and control HSC2/EGFP transfectant cells. They exhibited increased resistance to chemotherapeutic agents; 5-fluorouracil, cisplatin, docetaxel, trifluorothymidine, zoledronic acid, cetuximab, bortezomib and radiation when compared with HSC2 and HSC2/EGFP. Among all the transfected cells, HSC2/hOCT3/4-shp53-F + hSK + hUL cell containing all of the reprogramming factors showed the most aggressive and malignant properties and presented the highest number of spheres in the culture medium containing human recombinant fibroblast Growth Factor-2 (FGF-2) and epidermal Growth Factor (EGF). Conclusion: These findings suggest that artificial cancer stem cells obtained by the induction of cellular reprogramming may be useful for investigating the acquisition of potential malignancy as well as screening the CSCs-targeting drugs.

AB - Background: The cancer stem cells (CSCs), a small subpopulation of cells in tumor are responsible for the tumor initiation, growth, recurrence and metastasis of cancer, as well as resistance of cancers to drugs or radiotherapy. CSCs are an important target for the development of novel strategies in cancer treatment. However, CSCs-targeted new anti-cancer drug discovery is currently hindered by the lack of easy and reliable methods for isolating, collecting and maintaining sufficient number of CSCs. Here, we examined whether introduction of defined reprogramming factors (Oct4, shp53, Sox2, Klf4, l-Myc and Lin28) into HSC2 tongue cancer cells could transform the HSC2 into HSC2 with CSCs properties. Methods: We introduced the defined reprogramming factors into HSC2 tongue cancer cells via episomal vectors by electroporation method to generate transfectant cells. We investigated the malignant properties of the transfectant cells by cell proliferation assay, migration assay, wound healing assay, sphere formation assay, chemosensitivity and radiosensitivity assay in vitro; and also examined the tumorigenic potential of the transfectants in vivo. Results: The transfectant cells (HSC2/hOCT3/4-shp53-F, HSC2/hSK, HSC2/hUL, HSC2/hOCT3/4-shp53-F + hSK, HSC2/hOCT3/4-shp53-F + hUL, HSC2/hSK + hUL, HSC2/hOCT3/4-shp53-F + hSK + hUL) displayed a malignant phenotype in culture and form tumors on the back of nude mice more efficiently than parental HSC2 and control HSC2/EGFP transfectant cells. They exhibited increased resistance to chemotherapeutic agents; 5-fluorouracil, cisplatin, docetaxel, trifluorothymidine, zoledronic acid, cetuximab, bortezomib and radiation when compared with HSC2 and HSC2/EGFP. Among all the transfected cells, HSC2/hOCT3/4-shp53-F + hSK + hUL cell containing all of the reprogramming factors showed the most aggressive and malignant properties and presented the highest number of spheres in the culture medium containing human recombinant fibroblast Growth Factor-2 (FGF-2) and epidermal Growth Factor (EGF). Conclusion: These findings suggest that artificial cancer stem cells obtained by the induction of cellular reprogramming may be useful for investigating the acquisition of potential malignancy as well as screening the CSCs-targeting drugs.

KW - Artificial CSC

KW - Episomal vector

KW - Reprogramming factor

KW - Tongue cancer

UR - http://www.scopus.com/inward/record.url?scp=84979643101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979643101&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2416-9

DO - 10.1186/s12885-016-2416-9

M3 - Article

C2 - 27464948

AN - SCOPUS:84979643101

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 548

ER -